Fusion isoform multiplicity and impact on treatment outcomes in ALK-rearranged non-small cell lung cancer with next-generation tyrosine kinase inhibitors.

Humbert D, Buisson A, Basset M, Toffart AC, Odier L, Hominal S, Herreman C, Chabaud S, Pérol M, Mc Leer A, Swalduz A.

Open source

DOI
10.1016/j.lungcan.2026.109594
Published
2026-08-26
Container
Lung Cancer
Publisher
Not recorded
Open access
no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.lungcan.2026.109594,
  title = {Fusion isoform multiplicity and impact on treatment outcomes in ALK-rearranged non-small cell lung cancer with next-generation tyrosine kinase inhibitors.},
  author = {Humbert D and  Buisson A and  Basset M and  Toffart AC and  Odier L and  Hominal S and  Herreman C and  Chabaud S and  Pérol M and  Mc Leer A and  Swalduz A.},
  year = {2026},
  journal = {Lung Cancer},
  doi = {10.1016/j.lungcan.2026.109594},
  url = {https://doi.org/10.1016/j.lungcan.2026.109594}
}

RIS

TY  - JOUR
TI  - Fusion isoform multiplicity and impact on treatment outcomes in ALK-rearranged non-small cell lung cancer with next-generation tyrosine kinase inhibitors.
AU  - Humbert D
AU  -  Buisson A
AU  -  Basset M
AU  -  Toffart AC
AU  -  Odier L
AU  -  Hominal S
AU  -  Herreman C
AU  -  Chabaud S
AU  -  Pérol M
AU  -  Mc Leer A
AU  -  Swalduz A.
PY  - 2026
JO  - Lung Cancer
DO  - 10.1016/j.lungcan.2026.109594
UR  - https://doi.org/10.1016/j.lungcan.2026.109594
ER  - 

APA

D, H., A, B., M, B., AC, T., L, O., S, H., C, H., S, C., M, P., A, M. L., & A., S. (2026). Fusion isoform multiplicity and impact on treatment outcomes in ALK-rearranged non-small cell lung cancer with next-generation tyrosine kinase inhibitors.. Lung Cancer. https://doi.org/10.1016/j.lungcan.2026.109594

Source records